Key points are not available for this paper at this time.
Design
Review
Answers are grounded in this paper and cite their sources.
There remains a significant unmet medical need for safe and effective ventricular antiarrhythmic drugs, prompting ongoing pharmaceutical research into novel targets.
Ventricular antiarrhythmic drugs in current clinical use leave much to be desired in terms of safety and efficacy. With the exception of beta‐adrenoreceptor blockers, none of the available antiarrhythmic drugs have significantly improved survival after myocardial infarction. Amiodarone has shown marginal benefit but has several safety limitations. As a result, there is a large unmet medical need for a safe and effective drug to treat lethal ventricular arrhythmias. Despite the difficulties in developing such a drug, there are a few research programs dedicated to solving this unmet medical need. These include drugs that are targeted to the pathological substrate responsible for initiating arrhythmias and drugs that block multiple ion channels in a manner similar to amiodarone. A few research programs are directed toward other molecular targets. This article briefly reviews the active research programs in the pharmaceutical industry currently that are pursuing ventricular antiarrhythmic drugs. Drug Dev. Res. 55:45–52, 2002.
No takes yet. Share an insight, caveat, or question.
Beatch et al. (2002) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: